Incidence of Intussusception Among Infants in a Large Commercially Insured Population in the United States

被引:20
|
作者
Eng, Patricia Mona [1 ]
Mast, T. Christopher [2 ]
Loughlin, Jeanne [1 ]
Clifford, C. Robin [1 ]
Wong, Judy [1 ]
Seeger, John D. [1 ,3 ,4 ]
机构
[1] OptumInsight, Epidemiol, Waltham, MA 02451 USA
[2] Merck Res Labs, Dept Epidemiol, N Wales, PA USA
[3] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA
[4] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Pharmacoepidemiol, Boston, MA 02115 USA
关键词
cohort study; epidemiology; health insurance claims; rotavirus; CORONARY-HEART-DISEASE; ROTAVIRUS VACCINATION; SAFETY; CHILDHOOD; EFFICACY; CHILDREN; PROGRAM; TRENDS; RISK;
D O I
10.1097/INF.0b013e31824213b1
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: To estimate the incidence of intussusception among infants treated in inpatient and emergency department settings during the period preceding the US launch of second-generation rotavirus vaccines. Methods: From a large US health insurance claims database, we sampled 100,000 infants aged 1 to 3 months at first diphtheria-tetanus-acellular pertussis vaccination between 2001 and 2005. Potential intussusception cases were identified on the basis of claims and were confirmed by medical record review. Incidence rates (IRs) and 95% confidence intervals (CIs) were estimated based on follow-up from first diphtheria-tetanus-acellular pertussis dose to up to 1 year of age, and within 21, 30, and 60 days after each dose. Results: The IR of intussusception in the first year of life was 0.33/1000 person-years based on 22 confirmed cases (95% CI: 0.21-0.50/1000 person-years). The age-specific incidence peaked among infants aged 5 months (IR: 0.82/1000 person-years; 95% CI: 0.30-1.78/1000 person-years). During the 21, 30, and 60 days following any dose, the incidence per 1000 person-years was 0.27, 0.24, and 0.33, respectively. Conclusion: The rates described in this study can serve as a benchmark for comparison with incidences observed after the introduction of the second-generation rotavirus vaccines.
引用
收藏
页码:287 / 291
页数:5
相关论文
共 50 条
  • [41] ECONOMIC BURDEN OF SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) IN A COMMERCIALLY INSURED POPULATION IN THE UNITED STATES
    Oglesby, A. K.
    Durden, E.
    Narayanan, S.
    Juneau, P.
    Wilson, K.
    [J]. VALUE IN HEALTH, 2013, 16 (03) : A126 - A126
  • [42] Comorbidity Burden of Chronic Hepatitis B in a Commercially-insured Population in the United States
    Juday, Timothy
    Johnston, Stephen S.
    Wilson, Kathleen
    Quadri, Syed
    [J]. HEPATOLOGY, 2013, 58 : 624A - 624A
  • [43] PREVALENCE AND HEALTHCARE UTILIZATION BURDEN ASSOCIATED WITH RHINOSINUSITIS IN A UNITED STATES COMMERCIALLY INSURED POPULATION
    Khanna, R.
    Holy, C. E.
    Romano, A.
    [J]. VALUE IN HEALTH, 2017, 20 (05) : A349 - A349
  • [44] Geographic variation in the use of gabapentinoids and opioids for pain in a commercially insured population in the United States
    Zhao, Danni
    Baek, Jonggyu
    Hume, Anne
    Nunes, Anthony P.
    Alcusky, Matthew
    Lapane, Kate
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2021, 30 : 51 - 51
  • [45] Coccidioidomycosis Skin Testing in a Commercially Insured Population, United States, 2014-2017
    Benedict, Kaitlin
    McCotter, Orion Z.
    Jackson, Brendan R.
    [J]. EMERGING INFECTIOUS DISEASES, 2020, 26 (03) : 619 - 621
  • [46] A retrospective study of HIV antiretroviral treatment persistence in a commercially insured population in the United States
    Juday, Timothy
    Grimm, Kristy
    Zoe-Powers, Annette
    Willig, James
    Kim, Edward
    [J]. AIDS CARE-PSYCHOLOGICAL AND SOCIO-MEDICAL ASPECTS OF AIDS/HIV, 2011, 23 (09): : 1154 - 1162
  • [47] Patient characteristics, treatment patterns, and outcomes of Rickettsial diseases among a commercially insured population in the United States, 2005–2017
    Alison M. Binder
    Paige A. Armstrong
    [J]. Scientific Reports, 11
  • [48] GEOGRAPHIC VARIATION IN ON-LABEL AND OFF-LABEL TESTOSTERONE USE AMONG THE COMMERCIALLY INSURED POPULATION IN THE UNITED STATES
    Shewale, A. R.
    Bhandari, N. R.
    Kathe, N.
    Hammond, D.
    Painter, J. T.
    [J]. VALUE IN HEALTH, 2016, 19 (03) : A261 - A262
  • [49] Short Acting Beta Agonist Utilization and Risk of Asthma Exacerbation Among a Commercially Insured Pediatric Population in the United States
    Silver, H.
    Blanchette, C. M.
    Petersen, H.
    Kamble, S.
    Meddis, D.
    Gutierrez, B.
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2009, 123 (02) : S158 - S158
  • [50] Two-year persistence and compliance with osteoporosis therapies among postmenopausal women in a commercially insured population in the United States
    Durden, Emily
    Pinto, Lionel
    Lopez-Gonzalez, Lorena
    Juneau, Paul
    Barron, Richard
    [J]. ARCHIVES OF OSTEOPOROSIS, 2017, 12 (01)